INTERINDIVIDUAL VARIABILITY IN CYP2D6 ACTIVITY IN HUMAN LIVER MICROSOMES TO CHARACTERIZE RARE GENETIC VARIATION.

被引：0
|
作者：
Dalton, R. [1 ]
Phillips, B. [2 ]
Risler, L. [2 ]
Shen, D. D. [2 ]
Woodahl, E. L. [1 ]
机构：
[1] Univ Montana, Missoula, MT 59812 USA
[2] Univ Washington, Seattle, WA 98195 USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2015年 / 97卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PII-023
引用
收藏
页码：S65 / S66
页数：2
相关论文
共 50 条
  • [31] GENOTYPE- SENSITIVE REVERSIBLE AND TIME-DEPENDENT CYP2D6 INHIBITION IN HUMAN LIVER MICROSOMES
    Storelli, Flavia
    Desmeules, Jules
    Daali, Youssef
    DRUG METABOLISM AND PHARMACOKINETICS, 2019, 34 (01) : S41 - S42
  • [32] CYP2B6, CYP2D6, and CYP3A4 catalyze the primary oxidative metabolism of perhexiline enantiomers by human liver microsomes
    Davies, Benjamin J.
    Coller, Janet K.
    Somogyi, Andrew A.
    Milne, Robert W.
    Sallustio, Benedetta C.
    DRUG METABOLISM AND DISPOSITION, 2007, 35 (01) : 128 - 138
  • [33] Genotype-sensitive reversible and time-dependent CYP2D6 inhibition in human liver microsomes
    Storelli, Flavia
    Desmeules, Jules
    Daali, Youssef
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2019, 124 (02) : 170 - 180
  • [34] Variable contribution of CYP2D6 to the N-dealkylation of S-(-)-propranolol by human liver microsomes
    Rowland, K
    Ellis, SW
    Lennard, MS
    Tucker, GT
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 42 (03) : 390 - 393
  • [35] Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes
    Lundqvist, E
    Johansson, I
    Ingelman-Sundberg, M
    GENE, 1999, 226 (02) : 327 - 338
  • [36] Physiologically-based pharmacokinetic modeling of dextromethorphan to investigate interindividual variability within CYP2D6 activity score groups
    Ruedesheim, Simeon
    Selzer, Dominik
    Fuhr, Uwe
    Schwab, Matthias
    Lehr, Thorsten
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2022, 11 (04): : 494 - 511
  • [37] Assessment of Activity Levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 Genes by Population Pharmacokinetics of Dextromethorphan
    Abduljalil, K.
    Frank, D.
    Gaedigk, A.
    Klaassen, T.
    Tomalik-Scharte, D.
    Jetter, A.
    Jaehde, U.
    Kirchheiner, J.
    Fuhr, U.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 88 (05) : 643 - 651
  • [38] The Impact of the CYP2D6 "Enhancer" Single Nucleotide Polymorphism on CYP2D6 Activity
    Dinh, Jean C.
    Boone, Erin C.
    Staggs, Vincent S.
    Pearce, Robin E.
    Wang, Wendy Y.
    Gaedigk, Roger
    Leeder, James Steven
    Gaedigk, Andrea
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 (03) : 646 - 654
  • [39] Allele Drop Out Conferred by a Frequent CYP2D6 Genetic Variation For Commonly Used CYP2D6*3 Genotyping Assays
    Scantamburlo, Giada
    Tziolia, Konstantina
    Zopf, Michaela
    Bernardinelli, Emanuele
    Soyal, Selma M.
    Civello, Davide Antonio
    Vanoni, Simone
    Dossena, Silvia
    Patsch, Wolfgang
    Patrinos, George P.
    Paulmichl, Markus
    Nofziger, Charity
    CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2017, 43 (06) : 2297 - 2309
  • [40] Variation in the inhibitory potency of terbinafine among genetic variants of CYP2D6
    Akiyoshi, Takeshi
    Ishiuchi, Miho
    Imaoka, Ayuko
    Ohtani, Hisakazu
    DRUG METABOLISM AND PHARMACOKINETICS, 2015, 30 (04) : 321 - 324
12345